ATN

Welcome to the Brand page for “ATN”, which is offered here for Research and development of pharmaceuticals for the treatment of alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (als), huntington's disease, epilepsy, physical injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, infection, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, cerebral venous sinus thrombosis, retinal disease and other disease arising from neuronal damage; and testing, inspection, research or development of pharmaceutical preparations for gene therapy or small molecule treatment;amyloid tau neurodegeneration;astrocytes to neurons;.

Its status is currently believed to be active. Its class is unavailable. “ATN” is believed to be currently owned by “NeuExcell Therapeutics Inc.”